Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,373.94
(
0.05%
)
News Focus
News Focus
Post# of 257300
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 208848

Wednesday, 02/08/2017 9:56:26 AM

Wednesday, February 08, 2017 9:56:26 AM

Post# of 257300

GILD/ABBV/ENTA/MRK—What doesn’t the US like about V-Pak?

GT1 prevalence in the US is about 2/3 GT1a, where Viekira requires the use of ribavirin, crimping market share.

In Japan and major European countries, GT1 prevalence is about 2/3 GT1b. This benefits Viekira (compared to the US market) because Viekira does not require ribavirin for GT1b patients unless they have cirrhosis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today